Forest Cuts Combunox Detailing Following Disappointing Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Forest plans to reassign the combination pain therapy’s 1,100-person sales force to detail Lexapro, Namenda and the launch of nebivolol, pending FDA approval.
You may also be interested in...
Mylan Finds Its Way Out Of The Woods: Forest Signs Nebivolol Licensing Agreement
Forest will assume development, sales and marketing rights for Mylan's beta blocker.
Combunox's Future At Forest May Depend On Success Of New Trial Program
The future of Forest's combination pain therapy Combunox (oxycodone/ibuprofen)could depend on the success of a new product trial program launched in late September, the company suggested
NEJM, JAMA Editorials Give Opposing Opinions Of Mandatory HPV Vaccination
Two of the leading medical journals are offering opposing viewpoints on mandatory human papilloma virus vaccination, with experts contributing perspective pieces that directly reflect the larger political and social division over the issue